Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine is a research paper published in New England Journal of Medicine (2021). On theSindex it has a DataRank of 1.4. It has been cited 10,600 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
1.4
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institute of Allergy and Infectious Diseases
Grant: ACTG Leadership and Operations Center UM1 AI 68636
National Institute of Allergy and Infectious Diseases
Grant: HPTN Leadership and Operations Center UM1 AI 68619
National Institute of Allergy and Infectious Diseases
Grant: HVTN Laboratory Center UM1 AI 68618
National Institute of Allergy and Infectious Diseases
Grant: HVTN Leadership and Operations Center UM1 AI 68614
National Institute of Allergy and Infectious Diseases
Grant: HVTN Statistics and Data Management Center UM1 AI
National Institute of Allergy and Infectious Diseases
Grant: IDCRC leadership group 5 UM1 AI148684-03
Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority
Grant: Contract No. 75A50120C00034
National Institutes of Health
Grant: 3UM1AI148684-03S1
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)
National Institutes of Health
Grant: 3UM1AI068635-17S4
CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.
National Institutes of Health
Grant: 5UM1AI068619-09
LOC: HIV Prevention Trials Network
National Institutes of Health
Grant: 3UM1AI068618-16S1
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
National Institutes of Health
Grant: 3UM1AI068636-19SC
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Influential Citations
396
Fields of Study
Keywords
Sustainable Development Goals
Additional file 2 of A comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort study
Additional file 2 of A comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort study
Additional file 1 of Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial
Additional file 1 of Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial
Additional file 1 of Precision therapeutic targets for COVID-19
Additional file 1 of Precision therapeutic targets for COVID-19
Additional file 1 of Landscape and selection of vaccine epitopes in SARS-CoV-2
Additional file 1 of Landscape and selection of vaccine epitopes in SARS-CoV-2
Additional file 1 of Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials
Additional file 1 of Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials
Additional file 1 of Evaluation of the safety profile of COVID-19 vaccines: a rapid review
Additional file 1 of Evaluation of the safety profile of COVID-19 vaccines: a rapid review
Additional file 1 of Impact of an interactive web tool on patients’ intention to receive COVID-19 vaccination: a before-and-after impact study among patients with chronic conditions in France
Additional file 1 of Impact of an interactive web tool on patients’ intention to receive COVID-19 vaccination: a before-and-after impact study among patients with chronic conditions in France
Additional file 2 of Impact of an interactive web tool on patients’ intention to receive COVID-19 vaccination: a before-and-after impact study among patients with chronic conditions in France
Additional file 2 of Impact of an interactive web tool on patients’ intention to receive COVID-19 vaccination: a before-and-after impact study among patients with chronic conditions in France
Additional file 3 of Impact of an interactive web tool on patients’ intention to receive COVID-19 vaccination: a before-and-after impact study among patients with chronic conditions in France
Additional file 3 of Impact of an interactive web tool on patients’ intention to receive COVID-19 vaccination: a before-and-after impact study among patients with chronic conditions in France
Additional file 4 of Impact of an interactive web tool on patients’ intention to receive COVID-19 vaccination: a before-and-after impact study among patients with chronic conditions in France
Additional file 4 of Impact of an interactive web tool on patients’ intention to receive COVID-19 vaccination: a before-and-after impact study among patients with chronic conditions in France